<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00172198</url>
  </required_header>
  <id_info>
    <org_study_id>183CL1</org_study_id>
    <nct_id>NCT00172198</nct_id>
  </id_info>
  <brief_title>Omegaven (w-3 Fish Oil) Supplemented Parenteral Nutrition in Subjects of SICU.</brief_title>
  <official_title>A Prospective, Controlled, Randomized, Study Evaluating the Clinical Efficacy, Including Nutritional Status, Immune Function and Safety of Omegaven (w-3 Fish Oil) Supplemented Parenteral Nutrition in Subjects of SICU.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <brief_summary>
    <textblock>
      1. A prospective, controlled, randomized, study evaluating the clinical efficacy, including&#xD;
           nutritional status, immune function and safety of Omegaven (ω-3 fish oil) supplemented&#xD;
           parenteral nutrition in subjects of SICU.&#xD;
&#xD;
        2. Study patients are the critical ill patients in SICU of NTUH and the enrolled patients&#xD;
           will be 30 subjects ,including 15 in each treatment group.&#xD;
&#xD;
        3. During parenteral nutrition, fat emulsions will be given separately from amino acid and&#xD;
           glucose solutions. Infusion pump must be used.The recommended infusion duration of the&#xD;
           daily lipid emulsion is 16 hours (0.0625 g fat/kg B.W./hour) from 8:00 am to 12:00 pm.&#xD;
&#xD;
        4. During the study the assessments of safety and efficacy are to be performed according to&#xD;
           case report form. The assessment for safety variables including blood pressure、heat rate&#xD;
           、body temperature、liver function、renal function、coagulation、WBC、lipid profile etc. In&#xD;
           addition，the assessments for efficacy variables including&#xD;
           lymphocytes、cytokines(IL-1、IL-2、IL-6、IL-8、IL-11、IL-18、OX40&#xD;
           ligand、G-CSF、FN-γ、TGF-β1、TNF-α etc)、incidence of infections、 length of ICU and hospital&#xD;
           stay、mortality etc.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. A prospective, controlled, randomized, study evaluating the clinical efficacy, including&#xD;
           nutritional status, immune function and safety of Omegaven (ω-3 fish oil) supplemented&#xD;
           parenteral nutrition in subjects of SICU.&#xD;
&#xD;
        2. Study patients are the critical ill patients in SICU of NTUH and the enrolled patients&#xD;
           will be 30 subjects ,including 15 in each treatment group.&#xD;
&#xD;
        3. During parenteral nutrition, fat emulsions will be given separately from amino acid and&#xD;
           glucose solutions. Infusion pump must be used.The recommended infusion duration of the&#xD;
           daily lipid emulsion is 16 hours (0.0625 g fat/kg B.W./hour) from 8:00 am to 12:00 pm.&#xD;
&#xD;
        4. During the study the assessments of safety and efficacy are to be performed according to&#xD;
           case report form. The assessment for safety variables including blood pressure、heat rate&#xD;
           、body temperature、liver function、renal function、coagulation、WBC、lipid profile etc. In&#xD;
           addition，the assessments for efficacy variables including&#xD;
           lymphocytes、cytokines(IL-1、IL-2、IL-6、IL-8、IL-11、IL-18、OX40&#xD;
           ligand、G-CSF、FN-γ、TGF-β1、TNF-α etc)、incidence of infections、 length of ICU and hospital&#xD;
           stay、mortality etc.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2005</start_date>
  <completion_date>March 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lymphocytes:T4,T8,B,T,NK</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine secretion:IL-1、IL-2、IL-6、IL-8、IL-11、IL-18、OX40 ligand、G-CSF、FN-γ、TGF-β1、TNF-α.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical outcome:incidence of infections,length of ICU and hospital stay,ventilation,mortality</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver function(AST,ALT,bilirubin,ALP,rGT,albumin)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function(BUN,creatinine)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AC blood sugar</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>coagulation(INR,aPTT)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sodium</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>potassium</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chloride</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>calcium</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>magnesium</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total white blood cell counts</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelets</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>haemoglobin</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>haematoc</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Critical Ill Patients in SICU</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omegaven 10%</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients between 15 and 75 years of age&#xD;
&#xD;
          -  Expected ICU stay and TPN support requirement &gt; 7 days&#xD;
&#xD;
          -  Hemodynamically stable&#xD;
&#xD;
          -  Serum bilirubin &lt; 2.5 mg/dl&#xD;
&#xD;
          -  Serum creatinine &lt; 1.4 mg/dl&#xD;
&#xD;
          -  INR (international Normalized ratio of PT) &lt; 1.4&#xD;
&#xD;
          -  Written informed consent from the subject&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women. (Pre-menopause women, capable of bearing children will&#xD;
             undergo pregnancy test)&#xD;
&#xD;
          -  General contraindications of infusion therapy; acute pulmonary oedema,hyperhydration&#xD;
             and decompensated cardiac insufficiency&#xD;
&#xD;
          -  Known hypersensitivity to egg- or soy protein or any of the ingredients&#xD;
&#xD;
          -  Severe blood coagulation disorders&#xD;
&#xD;
          -  Shock necessitating acute resuscitation at the discretion of the investigator&#xD;
&#xD;
          -  Diabetes mellitus with known ketoacidosis within 7 days of onset of study treatment&#xD;
&#xD;
          -  APACHE II score &gt; 25&#xD;
&#xD;
          -  Renal insufficiency defined as serum creatinine value of &gt;1.4 mg/dl&#xD;
&#xD;
          -  Subjects with severe liver dysfunction which contraindicates the use of parenteral&#xD;
             nutrition at the discretion of the investigator&#xD;
&#xD;
          -  Known type IV hyperlipidemia, disturbances in lipid metabolism or hypertriglyceridemia&#xD;
             (at the time of inclusion, a blood sample (fasting) for serum triglyceride assessment&#xD;
             has to be taken. The sample has to be analysed before start of trial treatment. In&#xD;
             case of fasting serum triglyceride value of &gt;4 mmol/l (&gt;354 mg/dl) the subject must be&#xD;
             withdrawn.&#xD;
&#xD;
          -  Unconscious or uncooperative patients&#xD;
&#xD;
          -  Participation in a clinical study with an investigational drug or an investigational&#xD;
             medical device within one month prior to start of study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong-Shiee Lai, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital, Taipei, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hong-Shiee Lai, MD, PhD</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>5112</phone_ext>
    <email>hslai@ha.mc.ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong-Shiee Lai, M.D., Ph.D.</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>5112</phone_ext>
      <email>hslai@ha.mc.ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Roulet M, Frascarolo P, Pilet M, Chapuis G. Effects of intravenously infused fish oil on platelet fatty acid phospholipid composition and on platelet function in postoperative trauma. JPEN J Parenter Enteral Nutr. 1997 Sep-Oct;21(5):296-301.</citation>
    <PMID>9323693</PMID>
  </reference>
  <verification_date>January 2005</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>September 12, 2005</last_update_submitted>
  <last_update_submitted_qc>September 12, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2005</last_update_posted>
  <keyword>w-3 fish oil</keyword>
  <keyword>Nutrition</keyword>
  <keyword>immune</keyword>
  <keyword>intensive care</keyword>
  <keyword>patients</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

